Amedisys Reports Fourth Quarter and Year End 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Amedisys (AMED) Misses Q4 EPS by 2c, Offers Guidance
February 27, 2018 5:03 PM ESTAmedisys (NASDAQ: AMED) reported Q4 EPS of $0.56, $0.02 worse than the analyst estimate of $0.58. Revenue for the quarter came in at $404.2 million versus the consensus estimate of $394.62 million.
GUIDANCE:
Amedisys sees FY2018 EPS of $2.97-$3.08, may not compare to the consensus... More
